Ranganatha Potu, MD
Cardiovascular Disease · Crystal River, FLNPI 1801851217
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,022 of the $1,534 with a category attached, or 66.6%. Novo Nordisk AS accounts for 85.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $1,308 and has fallen 89.1% since, to $142 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in FL, where the typical reported total is $2,774.
Across 10 payments — averaging $153.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$1K
- Boston Scientific$125
- Philips North America LLC$72
- Abbott$17
- Merck$11
Across 414 payments — averaging $2441.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$562K
- Novo Nordisk AS$209K
- AstraZeneca$173K
- Esperion Therapeutics, Inc.$35K
- Boehringer Ingelheim International GmbH$14K
- Boehringer Ingelheim Pharma GmbH & Co.kg$11K
- plus $7K from 2 others
What the payments were for
- Travel & lodging$1,02267%
- Food & beverage$50133%
- Education$111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 6 | $1,308 |
| Boston Scientific | 1 | $125 |
| Philips North America LLC | 1 | $72 |
| Abbott | 1 | $17 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$125
How this compares
$1,534 in reported general payments places this provider in the 35th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 269 | $315,517 |
| XareltoRivaroxaban | 92 | $105,637 |
| EntrestoSacubitril/Valsartan | 61 | $97,527 |
| Repatha SureclickEvolocumab | 36 | $44,381 |
| JardianceEmpagliflozin | 16 | $25,602 |
| MultaqDronedarone Hcl | 13 | $12,279 |
| Valsartan | 119 | $4,388 |
| SotalolSotalol Hcl | 108 | $3,049 |
| Metoprolol Succinate | 179 | $2,774 |
| Bumetanide | 67 | $2,514 |
| Ranolazine ErRanolazine | 13 | $1,873 |
| Atorvastatin Calcium | 96 | $1,418 |
| ClopidogrelClopidogrel Bisulfate | 105 | $1,366 |
| Carvedilol | 142 | $1,284 |
| Potassium Chloride | 62 | $1,212 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Crystal River
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.